Clinical stage focus ORIC Pharmaceuticals is a clinical stage oncology company developing resistance-overcoming therapies, presenting a sales opportunity to partner for late-stage collaboration, out-licensing, or co-development arrangements around ORIC-944 and ORIC-114 as they advance through proofs of concept and potential expansion of indications.

Key assets Main candidates include ORIC-944, a PRC2 EED subunit inhibitor for prostate cancer, and Enozertinib (ORIC-114), a brain-penetrant EGFR exon 20 and HER2 exon 20 blocker for NSCLC, suggesting target-specific selling points for oncology franchises and potential combination therapy discussions.

Strategic visibility Active engagement in major conferences (AACR, ESMO, EORTC-NCI-AACR) with multiple posters and oral data highlights offers recurring outreach moments to raise visibility with investors, researchers, and potential strategic partners.

Funding and scale With revenue in the tens of millions and a recent funding level around $125 million, ORIC presents a credible partner profile for co-investment, aligned ecosystem players, and staged deals with biotech and pharma collaborators seeking oncology resistance mechanisms.

Geographic and team footprint Operations in South San Francisco and San Diego, combined with a mid-sized employee base, indicate a U.S. biotech hub presence suitable for regional BD activities, clinical collaborations, and local CRO/pilot partnerships for accelerated trial execution.